Investor mix
10 investors on record; 2 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 7 | 70% |
| Private equity | 1 | 10% |
| Other / undisclosed | 2 | 20% |
Small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation.
10 investors on record; 2 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 7 | 70% |
| Private equity | 1 | 10% |
| Other / undisclosed | 2 | 20% |